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Alternative conformations of the x region of human protein disulphide-isomerase 
modulate exposure of the substrate-binding b’ domain. 
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Protein disulphide-isomerase (PDI) is a key multi-domain protein folding catalyst in the endoplasmic 
reticulum. The b’ domain of PDI is essential for the non-covalent binding of incompletely folded protein 
substrates. We have previously defined the substrate binding site in the b’ domain of human PDI by 
modelling and mutagenesis studies. Here we show by fluorescence and NMR that recombinant human PDI 
b’x (comprising the b’ domain and the subsequent x linker region) can assume at least two different 
conformations in solution. We have screened mutants in the b’x region to identify mutations which favour 
one of these conformers in recombinant b'x and have isolated and characterised examples of both types. We 
have crystallised one mutant of b’x (I272A mutation) in which one conformer is stabilized, and determined 
its crystal structure to a resolution of 2.2Å. This structure shows that the b’ domain has the typical 
thioredoxin fold and that the x region can interact with the b’ domain by ‘capping’ a hydrophobic site on the 
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b’ domain. This site is most likely the substrate binding site and hence such ’capping’ will inhibit substrate 
binding. All of the mutations we previously reported to inhibit substrate binding shift the equilibrium 
towards the ‘capped’ conformer. Hence these mutations act by altering the natural equilibrium and 
decreasing the accessibility of the substrate binding site. Furthermore, we have confirmed that the 
corresponding structural transition occurs in the wild-type full-length PDI. A cross-comparison of our data 
with that for other PDI-family members, Pdi1p and ERp44, suggests that the x region of PDI can adopt 
alternative conformations during the functional cycle of PDI action and that these are linked to the ability of 
PDI to interact with folding substrates. 
 
Keywords: PDI, crystal structure, b' domain, alternative conformations, NMR 
 
Introduction 
The protein disulphide-isomerases (PDIs) are a family of proteins initially defined by their ability to 
assist the formation of native disulphide bonds in secretory and cell-surface proteins during their 
biosynthesis, but now characterised structurally by the presence of one or more thioredoxin-fold (trx) 
domains, and by their location within the lumen of the endoplasmic reticulum. The human PDI family is 
large (> 17 members) and the structures and specific roles of the multiple family members have not yet been 
defined1; the best-characterised is PDI itself, the archetype protein folding catalyst. PDI from a number of 
mammalian species has been studied for many years2 and its properties as a catalyst of disulphide-
interchange and associated protein folding are well-understood3-7. 
When mammalian PDI was first cloned and sequenced, it was immediately recognised that it 
comprised multiple homologous domains8 and subsequently the overall domain organization was defined as 
a-b-b’-x-a’-c, where a and a’ are trx domains containing the active site dithiol sequence WCGHC, b and b’ 
have the trx conformation but lack the active-site motif, x is a linker region and c is a C-terminal acidic tail9-
12. This domain organization was finally confirmed by the x-ray structural analysis of full-length yeast 
Pdi1p13-14. While the a and a’ domains of human PDI can catalyse simple thiol:disulphide interchange 
reactions, the presence of the b’ domain is essential for catalysis of protein disulphide isomerizations and for 
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non-covalent ligand binding15-16; the domains operate synergistically in linking catalytic and chaperone 
activities in protein folding10.  
The b’ domains of human PDI family members show greater sequence diversity than do the b, a and 
a’ domains, and studies with hybrid and chimaeric species indicate that the specificities of PDIs for ligands 
and partner proteins are primarily defined by their b’ domains; this has been confirmed in studies on the 
pancreas-specific isoform PDIp17, on the PDI homologue ERp57, which interacts specifically with the lectins 
calnexin and calreticulin18-21, and on the newly-described protein ERp2722 which comprises only b and b’-
like domains. These results make it of particular interest to study -- in molecular detail -- the b’ domains of 
PDIs and their interactions with ligands. Frustratingly, the b’ domain of human PDI is the only domain for 
which the structure has not been solved and for several members of the family (e.g. PDIp, ERp27), the b’ 
domains do not give good yields of well-folded soluble protein when expressed as recombinant constructs in 
E.coli. 
We previously reported the expression and characterization of the b’ and b’x domain fragments of 
human PDI, including defining the substrate binding site by modeling and mutagenesis studies12. In this 
paper we report further characterization of the recombinant b’x fragment and show that it exists in two 
distinct conformations which differ in tertiary structure, specifically in the environment of the unique Trp 
residue in the x region. From a screen of 75 mutants we identify mutants of b’x which exclusively adopt one 
or other of these alternative conformations. In addition, we report the crystal structure of one of these 
mutants, I272A; this reveals a hydrophobic pocket in the b’ domain capped by the x region. All of the 
mutations we previously reported to inhibit substrate binding12 shift the equilibrium in solution towards the 
capped conformer. Hence these mutations do not define the substrate binding site per se, but rather act 
indirectly to inhibit substrate binding by decreasing the accessibility of the substrate binding site. We present 
evidence that the two conformers are also significant in full-length PDI and suggest that these alternative 
conformations may explain some of the difficulties in characterizing the molecular properties of PDI and its 
sub-fragments and in understanding the ability of PDI to interact with folding substrates.  
 
Results 
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Preparations of recombinant human PDI b’x contain at least two conformers  
The domain boundaries of human PDI were defined in previous work11-12; the constructs studied here 
correspond to the complete b’ domain (P218-G332) and subsequent x region (K333-P351) with a short N-
terminal tag (MHHHHHHMKHNQL-). The b’ domain of human PDI contains no Trp residues, but there is a 
single Trp residue located in the x region (W347). Despite only having a single tryptophan, preparations of 
recombinant b’x gave a fluorescence emission spectrum with two maxima at approximately 334 nm and 355 
nm (Fig 1a and ref 12). Furthermore, in HSQC spectra of 15N-labelled human PDI b’x (Fig 1b) there were 
two peaks for the characteristic Trp indole sidechain resonance (shown boxed). There was, however, no 
indication of heterogeneity by mass spectrometry (data not shown). We have previously shown that b’x 
preparations give a CD spectrum consistent with substantial α-helix and β-sheet content and a single 
denaturation transition curve with a midpoint of 2.32 M guanidine hydrochloride12, both suggesting that the 
preparations do not contain any significant proportion of denatured protein. The fluorescence and NMR data 
in Figs 1a,b therefore indicate the possibility of conformational heterogeneity in the b’x preparations and we 
infer that the b’x fragment can exist in at least two alternative structured conformations. In one conformation 
(which we term the ‘capped’ form), the Trp residue in the x linker is buried in a hydrophobic environment, 
whereas in the other conformation (which we term the ‘uncapped’ form) the Trp residue is exposed to 
solvent. Analysis by fluorescence spectroscopy (Fig 1c,d) and CD (not shown) indicated that the ratio 
between these conformers could be altered by the applied salt concentration and that in dilute conditions at 
room temperature this salt-induced change in structure was reversible. 
  
Screening mutations that trap a single conformation of PDI b’x   
To generate homogenous preparations of the ‘capped’ and ‘uncapped’ conformers, we decided to 
screen for mutants in the b’x construct which might alter the conformer distribution, stabilising one relative 
to the other and allowing a single species to be characterised in detail. Since the fluorescence spectrum gave 
an easily-diagnosable read-out of the proportions of the ‘capped’ and ‘uncapped’ forms, this was chosen for 
the screen. In total 75 mutants of b’x were screened, a significant proportion of which were generated 
previously12. These mutants were purified on a micro-scale and their fluorescence spectra recorded in the 
elution buffer immediately after purification. Many of the mutants -- like the wild type protein -- showed a 
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mixed fluorescence spectrum with peaks at approximately 334 nm and 355 nm. However, some mutants 
showed a significant red-shift in fluorescence spectrum towards a single 355 nm peak (e.g. L343A, Fig 2a) 
while others showed a significant blue-shift towards a single 334nm peak (e.g. I272A, Fig 2b). Since the 
concentrations of the proteins obtained from the micro-scale purification varied by about three-fold, the 
parameter chosen to cross-compare spectra was the ratio of the average fluorescence at 331-337 nm to the 
average fluorescence at 352-358 nm. This ratio in elution buffer was 1.03 for the wild type protein and 
varied from 0.78 (extremely red-shifted) to 1.29 (extremely blue-shifted) for the mutant proteins (Fig 2c). 
Many of the mutations which resulted in a significant shift in the fluorescence ratio were either located in the 
vicinity of the substrate binding site as defined previously12 or were located in x. No significant differences 
were observed in the fluorescence ratios of the wild type, I272A or L343A mutant b’x constructs when 
excited at 280 or 295nm. 
 
NMR studies of PDI b’x constructs  
Two red-shifted and three blue-shifted mutants in b'x were chosen for purification to homogeneity 
on the milligram scale. Fluorescence analysis of these mutant proteins confirmed the results obtained from 
the micro-scale purification (data not shown). The CD spectra were characteristic of globular proteins with 
defined secondary structure, although the spectra were clearly different in detail from each other and from 
the wild-type protein (data not shown). The mutant proteins were generated in 15N-labelled form. HSQC 
spectra of the five mutants showed significant differences between them in resolved resonances, average line 
shape and dispersion.  The HSQC spectra of the blue-shifted mutants, I272A (Fig 3a), D346A/D348A and 
I272A/D346A/D348A (data not shown), gave well resolved spectra consistent with a folded protein of the 
expected molecular size. In contrast, the HSQC spectra of the red-shifted mutants, L343A (Fig 3b) and 
K349A (not shown), revealed both purified proteins as having poorly defined broad resonances characteristic 
of conformational exchange over the NMR experimental time scale due to significant structural differences 
and/or the presence of multimeric interactions. If we assume that the proportion of ‘uncapped’ and ‘capped’ 
forms can be judged from the intensity of the two resonances from the Trp indole HN, then the two red-
shifted mutants appear to be entirely in the ‘uncapped’ form, whereas all blue-shifted mutants had 
substantially less of the ‘uncapped’ form than the unfractionated wild-type sample (Fig 1b). The amount of 
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‘uncapped’ form was estimated for each blue-shifted mutant and found to decrease in the order 
D346A/D348A > I272A > the triple mutant I272A/D346A/D348A, with the triple mutant containing 
essentially none of this conformer. These results suggest that the blue-shift mutations act to stabilise the 
‘capped’ form relative to the ‘uncapped’ form and that the effect of the blue-shift mutations is additive.  
 
Crystallography of mutant PDI b’x   
Despite numerous attempts, we have been unable to obtain crystals from wild-type PDI b’ or b’x, a 
situation we tentatively assigned to the mixed conformers present. To test this hypothesis, we tried to 
crystallize the I272A and D346A/D348A mutants of human PDI b’x which had appeared by NMR to be 
predominantly in a single conformation. Both mutants gave crystals, but despite extensive optimization we 
were unable to improve the crystallization of the D346A/D348A mutant to obtain crystals which diffracted 
well. In contrast, we obtained crystals of the I272A mutant which diffracted well using 3 different conditions. 
Excluding the high B-factor loop which contains E304, E305 and E306, the crystals obtained under the three 
conditions gave structures whose backbone traces were effectively super-imposable. We chose to refine the 
structure of the pH 8.5 crystal, since the diffraction pattern was slightly better than that obtained at pH 7.5 
and since it is closer to physiological pH than the crystal obtained at pH 9.5. This structure has been refined 
at 2.2Å resolution (Table 1). There is one monomer per asymmetric unit. Seventeen residues were not 
observed in the electron density map, these being the three C-terminal residues (K349-P351) and fourteen N-
terminal residues comprising the His-tag and the first residue of the PDI sequence (P218). Therefore the 
ordered part of the b’x construct in the crystal structure extends from L219 to D348. The final model 
contains 2 cis-peptide bonds (C295-P296 and E304-E305). 
The crystal structure of the b’ domain of the I272A b’x construct (Fig 4a,b) unsurprisingly exhibits a 
PDI-type trx fold (ßαßαßαßßα). Part of the x region (residues P336-L338) forms an additional β-strand to the 
mixed β-sheet core of the trx fold and the rest of x loops round to remain juxtaposed to b’ with residues 
E345-W347 forming a short C-terminal helix.  
The b’ domain of PDI binds peptides and non-native proteins via predominantly hydrophobic 
interactions16-17 and hence a hydrophobic surface or solvent exposed hydrophobic pocket might be expected 
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on b’. Surface charge density maps (Fig 4c) of b’ reveal a hydrophobic pocket on one face of the domain 
which is capped by the x region (Fig 4d). Specifically, the side-chain of M339 (the first residue after the β-
strand in the x region) binds in a hydrophobic pocket comprising the sidechains of F287, F288, I301, M307 
and the alkyl chain of K309. The side-chains of L343 and W347 (further along the x region) also make 
hydrophobic interactions with the b’ domain and interact with the side-chains of F223, A228, F232, I284, 
F287, F288, L303, M307 in a broad site immediately adjacent to the binding pocket of M339. Residues F223, 
I284, F287 and F288 interact most closely with the side-chain of W347, and the site of mutation (A272) is 
located behind F223 which forms the bottom of this interaction pocket. The indole HN of W347 makes polar 
interactions with the side-chain carboxyl of E225 which also forms a salt bridge with the guanidino group of 
R283 on the top rim of the site (Fig 4d). It is noteworthy that the residues M339, L343 and W347 in the x 
region, and those forming the hydrophobic patches on the b’ domain with which they interact, are well 
conserved in PDI sequences of metazoan animal species.  
This hydrophobic location of the side-chain of W347 is consistent with the single peaked blue-
shifted fluorescence spectrum of this mutant. Structure analysis by Internal Coordinates Mechanics (ICM, 
Molsoft L.L.C., La Jolla, CA) shows vacancies in the structure with a total size of 50 Å3 adjacent to the 
A272 side chain. This is consistent with the difference in volume between the side chain of the isoleucine 
found in the wild-type protein at this position and the alanine found in the mutant, suggesting that the 
structure obtained for the mutant is valid for that of the wild-type b’x protein, or at least for the ‘capped’ 
conformer of it.  
 
Evidence for alternative conformations of the x region in full-length PDI 
Previously we showed that limited proteolysis of full length bovine PDI results in the formation of 
fragments in which the x region was associated either with the b’ domain or with the a’ domain, but that 
cleavage at an internal site in the x region was never observed23. This implies that the x region is structured 
and that this structure can be associated with either of the adjacent domains. While such an observation is 
consistent with the crystal structure of the capped conformer of b’x, care must be taken in interpreting 
proteolytic data in that conformational exchange of fragments can be different from that in the intact 
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molecule and in the case of PDI it is likely that proteolytic fragments will be bound by the substrate binding 
site and will therefore perturb any conformational exchange in the full length protein. 
Full length human PDI contains five tryptophan residues, two in the a domain (W35, W111), and 
two in a' (W379, W390), in addition to the one in x (W347). Hence its fluorescence emission is complex and 
it was not possible to use fluorescence to test whether the two conformational states (capped and uncapped) 
occur in the wild-type protein. The fluorescence of W35 in the WCGHC active site motif is very heavily 
quenched in both the dithiol and disulphide states24 and similarly W379 in the WCGHC active site motif of 
the a' domain would be expected to be heavily quenched. Hence in a W111F / W390F mutant PDI, the 
fluorescence of W347 would be expected to predominate. Micro-scale purification of this mutant revealed a 
tryptophan fluorescence spectrum that showed two distinct maxima (data not shown) though the spectrum 
overall was red-shifted compared to wild-type b’x (fluorescence ratio = 0.916 ±0.014, n=14). Informed by 
the b'x screen, two ‘blue-shift’ mutations (I272A and D346A/D348A) were then made in the W111F / 
W390F mutant background and both resulted in shifts towards the ‘capped’ form, similar to that observed in 
the isolated b’x construct (fluorescence ratios = 1.068 ±0.015 (n=7) and 1.021 ±0.009 (n=2) respectively). 
Similarly the ‘red-shift’ mutation L343A resulted in a shift towards the ‘uncapped’ form (fluorescence ratio 
= 0.865 ±0.005, n=3), though with a smaller shift than that observed for wild-type vs L343A b’x (see Fig 2). 
To confirm that the observed two-state nature of the fluorescence spectra was due to alternative 
environments of W347 in the x region, the quadruple-mutant W35F / W111F / W379F / W390F of PDI was 
made along with one ‘red-shift’ (L343A) and one ‘blue-shift’ (I272A) mutant in this background. As for the 
mutants in the W111F/W390F background, the L343A and I272A mutants in the ‘quadruple W-mutant’ 
background resulted in a ‘red-shift’ and ‘blue-shift’ respectively. However, proteolysis revealed that the 
additional mutations in W35 and W379 clearly destabilized the protein relative to wild type (data not shown). 
Overall the fluorescence data imply that the two conformers seen in the isolated b'x domain, corresponding 
to alternative environments for the x region, also occur in full length PDI and that the relative proportions of 
each conformer are affected in the same way by the same mutations. However, all of these fluorescence data 
were obtained from mutated forms of PDI. 
To examine whether the conformational exchange occurs in wild type full length PDI, NMR based 
analysis was undertaken. Full length human PDI is 55kDa, too large for a full structural analysis. Instead we 
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focused on the indole region of the 15N-1H HSQC spectrum as we had already observed a good correlation 
between shifts in fluorescence spectra and shifts in peak intensities in this region (see Figs. 1-3). 
Assignments of the individual indole resonances in full length PDI were confirmed from a series of HSQC 
experiments where tryptophan residues were systematically mutated to phenylalanine in the full length 
protein and from studies on the isolated a domain. The indole resonance of W347 in wild-type b’x was seen 
as two peaks, showing the presence of both ‘capped and ‘uncapped’ species that can be individually defined 
as distinct single peaks in the mutants b’x I272A/D346A/D348A (capped) and b’x L343A (uncapped) (Fig. 
5). Asymmetric line broadening of the W347 indole resonance in the 15N-1H HSQC spectrum of full length 
wild type PDI tracks between the observed ‘capped’ and ‘uncapped’ indole resonances from both wild-type 
and mutant b’x samples (Fig. 5). This indicates that W347 in full length wild-type PDI also experiences 
conformational exchange between ‘capped’ and ‘uncapped’ forms. 
Previously there has been a debate on whether substrate binding by PDI is redox modulated25-26. No 
significant redox dependent changes were seen in the fluorescence spectra of wild type, I272A or L343A 
mutant b’x constructs or in the full length PDI W111F/W390F construct. Furthermore there was no 
significant redox-dependent difference in the appearance of the W347 resonance in the 15N-1H HSQC 
spectrum of full length wild type PDI. These observations indicate that there is no redox dependence for the 
conformational exchange between the ‘capped’ and ‘uncapped’ conformers and are consistent with the report 
that PDI is not a redox-dependent molecular chaperone26. 
 
Discussion 
A high resolution structure of the b’x region of human PDI   
The biological significance of mammalian PDI in the folding of disulphide-bonded secretory 
proteins has been clear for many years2 and throughout that time pure protein has been abundantly available, 
either from mammalian tissues or recombinant sources27-28. No high-resolution structure of a full-length PDI 
from a multicellular organism has been achieved to date, despite the fact that many groups have attempted to 
determine the structure of PDIs by x-ray crystallography. This may reflect inter-domain flexibility or the 
existence of regions within the full-length molecule that can adopt alternative conformations. The structures 
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of individual a, b and a’ domains of human PDI have been determined by NMR, but it is interesting that no 
structure has been achieved by this approach for the b’ domain or the combination of b’ domain and adjacent 
x linker region. The difficulty in previous studies of the b’ domain or b’x combination could have arisen 
from poor definition of the domain boundary, but it is possible that this domain does show some intrinsic 
flexibility or conformational heterogeneity. 
In the current paper we have analysed recombinant human b’x in detail -- using a range of 
techniques for structural study in solution -- and identified the existence of at least two conformational states 
which clearly differ in the structural relationship between the x region (specifically W347) and the b’ domain. 
In order to overcome the complexities introduced by the existence of these states, we sought to generate 
mutants which might preferentially stabilize one state and eliminate the conformational heterogeneity. Using 
fluorescence screening we were able to identify mutants which preferentially adopted one or other 
conformation and we have crystallized and determined the structure of the I272A mutant of b’x, which we 
inferred to be entirely in the ‘capped’ conformation. In accordance with our inference from solution studies 
on this mutant and on wild-type b’x, the x region is intimately associated with the b’ domain in the crystal 
structure of b’x I272A, and the indole side-chain of W347 is buried in a hydrophobic pocket.  
 
Comparison with b’ and x conformations in other PDI family structures   
In Fig 6a we show a structure-based sequence alignment of the human PDI b’x region with the 
corresponding region of yeast Pdi1p, based on the structure of I272A b’x solved here (“capped b’x”) and on 
the full-length structure of Pdi1p13. This shows that, overall, the two b’ domains adopt very similar 
conformations with the exception of the region of Pdi1p (residues 330-344 in mature Pdi1p numbering) 
which forms a loop and a short additional helix. In capped human PDI b’x, this region comprises simply a 
short loop linking β5 directly to α4. A superposition of the backbone atoms (N, Cα, C) for the core β-strands 
(42 residues) of yeast and capped human b’x using the alignment in Fig 6a gave an RMSD of 0.6Å; this 
value increased to 1.5Å when both β-strands and helices were included (102 residues). Comparison using 
DALI29 of capped human b’x to all structures in the protein databank found close similarities with the b’ 
domains of other PDI-family members including the bb’ fragment of human ERp57 (2h81), the b’ domain of 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 11 
yeast Pdi1p (2be5), the bb’ fragment from human PDI (2k18; structure released whilst this manuscript was 
in review) and the b’ domain from the thermophilic fungus Humicola insolens (2djk) along with other 
thioredoxin fold containing proteins. 
However there is a major difference between the human and yeast PDI structures in the orientation 
of the x region, which in the Pdi1p structure does not cap the hydrophobic surface of b’ as is observed for 
capped human PDI b’x (Fig 6b). Were human PDI b’x to adopt such an arrangement as found in yeast Pdi1p, 
W347 in the x region would be solvent exposed and probably highly mobile, consistent with the fluorescence 
data for the ‘uncapped’ conformer of the wild-type human b’x protein. We infer that the structure of the 
‘uncapped’ conformer of wild-type human b’x has some similarities to that observed in the crystal structure 
of yeast Pdi1p and that the identified ‘red-shifting’ mutations act by stabilising this structure in isolated 
human b’x.  
In analyzing their structure of yeast Pdi1p, Tian et al.13 drew attention to a ‘highly hydrophobic 
pocket’ on the surface of the b’ domain (Fig 6b) which – together with hydrophobic patches at homologous 
positions on the surfaces of the a, b and a’ domains – forms a continuous hydrophobic surface. We had 
previously proposed that the b’ domain provided the principal binding site on PDI for peptides and unfolded 
proteins, based on studies on human PDI domains and domain combinations12,16. Functional studies on yeast 
Pdi1p mutants by Tian et al.13 confirm that this conclusion is also valid for the yeast enzyme. In Fig 6a, the 
residues which contribute side-chains to the ‘highly hydrophobic pocket’ identified by Tian et al.13 are 
highlighted and the corresponding residues in the structurally-aligned human sequence are also highlighted. 
Also in Fig 6a, we identify the residues of the b’ domain of human b’x which form hydrophobic contacts 
with the sidechains of L343 and W347 of the x linker. It is clear that the x linker is retained in close contact 
with the b’ domain by binding in the centre of a wider hydrophobic surface which corresponds to the 
hydrophobic pocket identified by Tian et al.13 in the yeast Pdi1p structure and which has been identified as 
the putative ligand binding site (Fig 6b). Hence the interaction of x with b' probably mimics substrate 
binding. 
Previously we identified the substrate binding site in PDI by a combination of modelling and 
mutagenesis studies12. The binding site identified by those studies was not based on a high resolution 
structure and does not match that identified here or by Tian et al.13. However, all of the mutations previously 
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identified to inhibit substrate binding (including I272A) are blue-shift mutants (compare data presented in 
reference 12 with that in fig 2c). Hence these mutations are not in residues directly involved in interaction 
with substrates but rather they act indirectly by stabilizing the conformer in which the hydrophobic pocket is 
‘capped’ by x relative to the ‘uncapped’ conformer. Hence our previous results showing that these mutations 
in b'x or full length PDI result in a loss of ability to bind substrates suggest that, once capped by x, the 
substrate binding site is unavailable to bind substrates. 
 
Functional significance of novel structural interaction between b’ domain and x linker   
This work has i) demonstrated that there is an intrinsic conformational heterogeneity in isolated 
human PDI b’x between conformers which differ in the structural relationship between the b’ domain and 
the x region, ii) determined the structure of a mutant b’x showing an interaction between parts of the x 
region and sites on the b’ domain, and iii) confirmed that, in this structure, x is interacting with a 
hydrophobic site homologous to that postulated as the ligand binding site in the structure of full-length yeast 
Pdi1p. Hence it appears that the x region can adopt alternative conformations and can potentially exchange 
between the ‘capped’ conformation, in which it occludes a site on the b’ domain, and an ‘uncapped’ 
conformation which reveals this site. Furthermore we have demonstrated that a similar conformational 
exchange happens in full length human PDI with the x region capable of interacting reversibly with the 
principal substrate binding site. It is likely that this is significant as part of the function of the enzyme in 
facilitating protein folding. The existence of such alternative conformations for the x region in full-length 
PDI provides one explanation why the structure of full-length mammalian PDI has been so resistant to 
determination by x-ray crystallography. However it is not the only reason as the full length human PDI 
I272A mutant appears to be intransigent to crystallization. It is significant that the structure of yeast Pdi1p 
was generated from a slowly-developing crystal form in which one molecule of the protein occupies the 
putative ligand binding site of a second, symmetry-related molecule13; this may have the effect of trapping 
the protein in the ‘ligand-bound’ form and inhibiting conformational exchange. This suggests that the yeast 
structure represents a conformation in which a protein ligand is bound, displacing the x linker, whereas the 
human b’x structure represents an alternative ligand-free state, and that both these conformations may be 
relevant to the functional cycle of the enzyme. It is well-known that in the functional cycle of GroEL/ES, the 
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hydrophobic binding site in the apical domain of GroEL that binds unfolded protein substrates alternates 
between being available for binding such ligands and being occluded by interaction with part of the GroES 
cap30; the interconversion between such states involves relative re-orientations of the domains of the 
chaperonin molecule. Such re-orientations between domains (and especially of the x linker relative to its 
neighbouring domains) may be a critical feature of the functional cycle of PDI and the process of such re-
orientations in preparations of full-length PDI may generate the conformational heterogeneity which has 
frustrated previous structural studies. 
During the preparation of this manuscript data supporting the notion that this conformational 
exchange may be linked to function has emerged. The crystal structure of human ERp44, a PDI-family 
member with the domain architecture a-b-b’, revealed that the C-terminal tail caps both a hydrophoic pocket 
in the b’ domain thought to be the substrate binding site and a region close to the active site in the catalytic a 
domain31. The structure of the capped b’ domain of ER44 is remarkably similar to that of the capped b’ 
domain of human PDI we report here (Fig. 7). A superposition of the backbone atoms (N, Cα, C) for 19 
residues in structurally analogous positions across all 5 β-strands gave a RMSD of 0.57Å. Likewise the 
nature of the interaction of the carboxy terminal extension with the hydrophobic pocket in ERp44 is similar 
to that of the x region capping the binding site in the b’ domain of PDI, with L361 in ERp44 playing a role 
similar to that of W347 in PDI. Deletion of the C-terminal tail in ERp44 increased the activity of ERp44 and 
its ability to act as a molecular chaperone31, both consistent with a regulatory role for the tail. The emergence 
of two such similar structures suggests that this may be a common regulatory mechanism within the PDI 
family. 
 
Materials and Methods 
Mutagenesis, expression and purification  
The plasmid containing the gene encoding the human PDI b’x domain fragment is a derivative of 
pET23b (Novagen). The resulting protein is expressed with an N-terminal His tag MHHHHHHM and 
encodes residues K213 to P351 of mature PDI. Mutagenesis, transformation, expression and purification 
were done as described previously12.  
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 Purification on a micro-scale from 5-10 ml of bacterial culture for fluorescence screening of mutants 
was done using Ni-NTA spin columns (Qiagen) according to the protocol recommended by the manufacturer. 
 
Spectroscopy 
Fluorescence spectra were measured on a Perkin/Elmer LS50 fluorometer (excitation 280 nm or 
295nm for b’x and 295nm for the full length protein, emission 300-400 nm or 320-400nm, slit widths 5 nm, 
scan speed 200 nm/min, average of 4 scans, 25°C). CD spectra were measured on a Jasco J-815 CD (0.1 mm 
cuvette, 250-190 nm, step resolution 0.2 nm, response 0.25 s, bandwidth 1 nm, scan speed 20 nm/min, 
average of 8 scans, 25°C) 
 
NMR spectroscopy 
Cells were grown in minimal medium to allow isotopic labeling using 1 g/l 15N ammonium sulphate 
as sole nitrogen source and labelled protein was expressed and purified as described previously12. Samples 
for NMR analysis were concentrated to between 0.36 mM and 1 mM in 20 mM phosphate buffer (pH 6.5) 
containing 150 mM NaCl by centrifugation on Vivaspin columns with a 5 kD cut-off and then D2O added to 
a final concentration of 10% (v/v). 15N/1H HSQC spectra were collected at 25°C as described in Alanen et 
al.22. 
 
Crystallization 
To prepare selenium-labelled protein a fresh colony of E.coli B834(DE3) carrying plasmid pAKL73 
encoding for human PDI b’x I272A was inoculated into 200 ml of sterile M9 minimal medium with an 
additional 0.5 mM L-methionine at 37oC for 20 hours. The bacteria were collected by centrifugation and 
washed twice with 200 ml of sterile water. The bacteria were then resuspended in M9 medium with an 
additional 0.5 mM of selenomethionine to an OD600 of 0.3 and grown at 37
oC, 200 rpm to an OD600 of 0.7 
and then induced with 1 mM of IPTG at 25oC, 200 rpm, for 12 hours. The bacteria were then harvested by 
centrifugation, resuspended in 1/10 volume 20 mM phosphate pH 7.3, DNase added to final concentration of 
10 µg/ml and lysozyme to final concentration of 1 mg/ml and then frozen. The protein was purified as for 
non-labelled protein. 10 mg of purified Se-labeled protein was obtained from 1 litre of culture. 
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Crystals of the SeMet derivative were obtained after one week by the hanging-drop, vapour diffusion 
equilibration method32 using 2 µl of protein solution (10 mg/ml) and 2 µl well solution (0.2 M NaCl, 2.95 M 
ammonium sulfate, 0.1 M Tris-HCl buffer pH 9.5) at 22oC. Crystals of unlabelled protein were obtained by 
the same method at pH 7.5, 8.5 and 9.5. Crystals were harvested from drops, put into paraffin oil for a few 
seconds and then frozen in liquid nitrogen. X-ray data were collected at cryogenic temperature (100 K). 
 
Data collection, structure determination and refinement 
Multiwavelength anomalous dispersion (MAD) data were collected for the Se-Met crystal on CCD 
detector at beamline BW7A (DESY, Hamburg, Germany). The x-ray data from native crystals at pH 7.5, 8.5 
and 9.5 were collected at X12 (DESY, Hamburg, Germany). Images were processed using the XDS program 
package33-34. Using the Auto-RickShaw protocol35-36, the MAD-dataset resulted in the initial model that was 
completed with COOT37. Subsequently the structure of the native datasets were refined using REFMAC538 
with the translation libration screw (TLS) description of the anisotropic rigid body motion39. The data 
collection statistics and refinement statistics of the pH 8.5 structure are given in Table 1. The model includes 
45 waters and one sulphate ion. 
 
Protein Data Bank accession code 
The atomic coordinates and structure factors of the b’x domain of human PDI have been deposited 
in the Protein Data Bank with accession code 3BJ5. 
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Figure legends 
Figure 1. Spectroscopic properties of human PDI b’x 
(a) Representative relative fluorescence emission spectrum, excitation at 280nm, and (b) 15N/1H HSQC NMR 
spectrum for purified wt protein. Emission maxima at 334nm and 355nm are indicated by the dotted and 
dashed lines respectively and the position of the two Trp indole cross-peaks in (b) are shown by the dashed 
box. (c and d) Shift in fluorescence spectra upon changing the ionic strength of the solution. (c) b’x (4.4 
mg/ml) pre-incubated in 20 mM phosphate buffer, pH 7.3, and (d) b’x (4.4 mg/ml) pre-incubated in 20mM 
phosphate buffer, pH 7.3, containing 1.0M sodium chloride. Both (c) and (d) were pre-incubated for 30 
minutes at room temperature and then fluorescence emission spectra collected at 25oC after diluting 100-fold 
into 20mM phosphate buffer (solid line) or 20mM phosphate buffer plus 1.0M sodium chloride (dashed line). 
Separate kinetic measurements showed that the interconversion between the two forms occurred within the 
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manual mixing time. Similar shifts in fluorescence spectra were observed using a range of salt solutions 
indicating that the effects were dependent on ionic strength and not specific to the salt used. (AU = arbitrary 
units) 
 
Figure 2. Screening of b’x mutants to identify mutations stabilising a single conformer 
Representative relative fluorescence emission spectra, excitation at 280nm, of micro-scale preparations of (a) 
L343A and (b) I272A mutants of human PDI b’x. Emission maxima at 334nm and 355nm are indicated by 
the dotted and dashed lines respectively. (c) Shifts in fluorescence ratios (331-337nm/352-358nm) for all 75 
mutants of human PDI b’x relative to the wild type protein (wild type fluorescence ratio = 1.03). The data 
shows the mean from at least 2 independent measurements and the horizontal dashed lines correspond to a 
ratio of +/- 0.15 from the mean value for the wild-type. The mutants L343A and I272A are shown with open 
boxes. 
 
Figure 3. NMR studies of b'x mutants 
15N/1H HSQC NMR spectra of (a) I272A and (b) L343A mutants. The position of the Trp indole cross-peaks 
is shown by the dashed box. 
 
Figure 4. Crystal structure of b’x I272A 
(a) Ribbon diagram showing the trx fold of b’x with the x region coloured in green. (b) Rotation of the above 
structure through approx. 90 degrees along both the x- and z-axes to bring the x region to the front of the 
molecule. The side-chains of M339, L343 and W347 are shown as green sticks. (c) Surface charge density 
map for the b’ domain in the same orientation as shown in (b) with the x-region shown in ribbon format. 
Blue = positive potential, red = negative potential, white = neutral. (d) Expanded view of the x-region 
binding site. The sidechains of residues F223, A228, F232, I284, F287, F288, L303 and M307 are coloured 
magenta and form a broad hydrophobic site in which residues L343 and W347 are bound. The sidechains of 
I301 and the alkyl chain of K309 are coloured light blue and together with F287, F288, M307 (coloured 
magenta) form a binding pocket for M339. The sidechains of E225 and R283 (charged atoms coloured grey) 
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form a salt bridge on the top rim of the binding site close to the indole HN of W347. This figure was 
produced using MOLMOL40. 
 
Figure 5. Conformational exchange in the environment of W347. 
Overlay of the tryptophan indole regions of 600 MHz 15N-1H HSQC NMR spectra of PDI b’-x L343A 
mutant (red), b’x I272A/D346A/D348A mutant (blue), b’x wild-type (green) and full length PDI (black). 
Assignments of all full length PDI indole resonances are indicated. 
 
Figure 6. Structural comparison of human and yeast b’x domains  
(a) Structure-based alignment of the human and yeast b’x sequences. A cyan background denotes residues 
identified as part of the hydrophobic binding site in the yeast structure13 and the corresponding residues in 
the human protein. Two further residues (F287 and M307) appear to contribute to the human hydrophobic 
site (shown underlined in red) whereas two residues (N281 and R299) appear to fall outside the site (shown 
underlined in black). Residues in the human sequence coloured red comprise the binding site for L343 and 
W347 as judged from the b’x structure (at least one side-chain to side-chain atom distance within 5Å). The x 
region for both sequences is shown on a grey background with the hydrophobic residues in x important for 
interaction with b’ shown in green. The residue numbering is for the mature protein in both cases and the 
secondary structure assignments (as defined in the pdb header for yeast (2b5e) and using the Kabsch and 
Sander algorithm as implemented in MOLMOL39 for human) are shown above or below the sequence as 
appropriate. (b and c) Surface representation of the hydrophobic binding sites as defined in the sequence 
alignment above (those residues highlighted in cyan and underlined in red) for yeast and human b’x 
respectively. The side-chains of the hydrophobic sites are shown in white whilst the backbone and all other 
b’ residues are coloured blue. The x regions are shown in ribbon format and the side-chains of M339, L343 
and W347 in the human structure are shown in green. The two views are in the same orientation (achieved 
by superposition of the core β-sheet) corresponding to that in Fig 4b and c. This figure was generated using 
MOLMOL40. 
 
Figure 7 Structural comparison of human PDI b’x and ERp44 
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The two structures are shown in the same orientation as determined by superposition of their β-strands. The 
x region is shown in green for human PDI and magenta for ERp44. The sidechains of the residues important 
for hydrophobic interaction of x with b’ (L343 and W347 in PDI, and F358 and L361in ERp44) are also 
shown. The sidechain of L361 in ERp44 is in an analogous position to W347 in PDI.  
 
 
 
Table 1. Crystallographic statistics of the structure of the non-labelled human PDI b’x domain I272A mutant 
grown at pH 8.5 as processed by XDS. The values in parentheses are for the highest resolution shell. 
 
Data collection statistics
 
 
Space group P3(1)21 
Unit cell parameters. 
   a, b, c (Å)  
    
57.37, 57.37, 68.31 
Temperature (K) 100 
Wavelength (Å) 0.89997 
Resolution (Å) 50-2.2  
Rmerge (%) 5.5 (29.3) 
Completeness (%) 99.3 (99.6) 
I/σI 17.84 (5.0) 
Unique reflections 6879 (849) 
Redundancy 4.3 (4.4) 
Mosaicity (°) 0.17 
B-factor from Wilson plot (Å2) 41 
Refinement statistics  
Resolution (Å) 50-2.2 
Total number of reflections  6877 
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Working set: number of reflections 6533 
Rfactor (%) 19.4 
Test set: number of reflections 344 
Rfree (%) 25.5 
Protein atoms 1063 
Water atoms 45 
SO4
2-  atoms 5 
Geometry statistics  
Rmsd (bond distance) (Å) 0.012 
Rmsd (bond angle) (°) 1.4 
Rmsd B 
Main chain bonded atoms (Å2) 
Side chain bonded atoms (Å2) 
Main chain angle (Å2) 
Side chain angle (Å2) 
 
0.8 
1.8 
1.3 
2.8 
Average B 
Main chain atoms (Å2) 
Side chain atoms (Å2) 
Water molecules (Å2) 
Sulfate atoms (Å2) 
 
 
36.4 
37.7 
39.5 
80.7 
 
Ramachandran plot 
Most favored region (%) 
Additionally allowed regions (%) 
Generously allowed regions (%) 
Disallowed regions (%) 
 
94 
6 
0 
0 
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